Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (10) , 794.e11-794.e16
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Institutes of Health (HL069438)
- National Institutes of Health (DK056638)
- National Institutes of Health (DK112976)
- National Institutes of Health (DK116312)
- National Institutes of Health (T32 GM007288)
This publication has 26 references indexed in Scilit:
- Biologic correlates and significance of axonogenesis in prostate cancerHuman Pathology, 2014
- Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic DiseaseEuropean Urology, 2014
- Future directions in the prevention of prostate cancerNature Reviews Clinical Oncology, 2013
- Norepinephrine antagonists and cancer riskInternational Journal of Cancer, 2010
- Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination SurveyJournal of Clinical Oncology, 2010
- Cancer-Related Axonogenesis and Neurogenesis in Prostate CancerClinical Cancer Research, 2008
- Cardiovascular Protection Using Beta-BlockersJACC, 2007
- Cardiovascular drug class specificity: β-blockersProgress in Cardiovascular Diseases, 2004
- Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the ratNaunyn-Schmiedeberg's Archives of Pharmacology, 1985
- Innervation of the ventral prostate of the ratJournal of Anatomy, 1979